Lead Product(s) : Usnoflast
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zydus received permission to initiate the Phase II (a) clinical study of its NLRP3 inhibitor ZYIL1 for the treatment of Cryopyrin-Associated Periodic Syndrome.
Product Name : ZYIL1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 13, 2021
Lead Product(s) : Usnoflast
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable